BBIO BridgeBio Pharma, Inc.
Stock · NasdaqGS · United States · Healthcare · US10806X1028
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by BridgeBio Pharma, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
74.29 USD
+0.03%
52-week range
60.55 – 93.42
Dividend yield—
Market cap14.5B
NowoTrade score
26 Grade A
Price history
Daily prices in USD.
Updated 06 Nov 2026 21:26. Information, not advice.
Results
Next results
23 Feb 2027
in 108 days · 16:00 · estimate -0.44
Last results
-0.42 vs -0.56 estimated
29 Oct 2026 · Beat +24.6%
Beat the estimate
3 of 12
8 missed · 1 in line
Average surprise
-12.2%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 23 Feb 2027 16:00 | -0.44 | — | — | Upcoming |
| 29 Oct 2026 16:00 | -0.56 | -0.42 | +24.6% | Beat |
| 10 Aug 2026 16:00 | -0.58 | -0.78 | -33.9% | Miss |
| 07 May 2026 16:00 | -0.62 | -0.84 | -36.2% | Miss |
| 24 Feb 2026 16:00 | -0.62 | -0.94 | -50.6% | Miss |
| 29 Oct 2025 16:00 | -0.78 | -0.72 | +7.7% | Beat |
| 05 Aug 2025 16:00 | -0.60 | -0.95 | -57.1% | Miss |
| 29 Apr 2025 16:00 | -1.00 | -0.99 | +0.9% | In line |
| 20 Feb 2025 07:00 | -1.09 | -1.37 | -26.1% | Miss |
| 12 Nov 2024 07:00 | -0.86 | -1.08 | -25.1% | Miss |
| 01 Aug 2024 07:00 | -0.94 | -1.01 | -7.2% | Miss |
| 02 May 2024 07:00 | -0.54 | -0.12 | +77.0% | Beat |
| 22 Feb 2024 07:00 | -0.80 | -0.96 | -20.1% | Miss |
| 02 Nov 2023 07:00 | -0.89 | -1.08 | -21.6% | Miss |
| 03 Aug 2023 07:00 | -0.87 | -0.96 | -9.9% | Miss |
| 04 May 2023 07:00 | -0.83 | -0.90 | -7.7% | Miss |
| 23 Feb 2023 07:00 | -0.94 | -0.87 | +7.3% | Beat |
| 03 Nov 2022 07:00 | -1.01 | -0.89 | +11.3% | Beat |
| 04 Aug 2022 07:00 | -0.86 | -0.75 | +13.7% | Beat |
| 05 May 2022 07:00 | -1.10 | -1.19 | -8.8% | Miss |
| 24 Feb 2022 07:00 | -0.91 | -1.01 | -11.5% | Miss |
| 04 Nov 2021 07:00 | -0.91 | -1.06 | -16.4% | Miss |
| 05 Aug 2021 07:00 | -0.89 | -0.66 | +26.0% | Beat |
| 06 May 2021 07:00 | -0.75 | -1.18 | -57.1% | Miss |
| 25 Feb 2021 07:00 | -0.86 | -1.01 | -17.4% | Miss |
| 05 Nov 2020 07:00 | -0.89 | -0.98 | -10.6% | Miss |
| 11 Aug 2020 07:00 | -0.73 | -1.03 | -41.9% | Miss |
| 13 May 2020 16:00 | -0.70 | -0.78 | -12.1% | Miss |
| 02 Mar 2020 08:00 | -0.63 | -0.62 | +0.9% | In line |
| 07 Nov 2019 16:00 | -0.54 | -0.51 | +5.0% | Beat |
| 14 Aug 2019 06:00 | -0.40 | -0.56 | -38.4% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 502.1M | +126.3% | -724.9M | -144.4% | -3.78 | -31.3% | -455.5M |
| 2024 | 221.9M | +2,285.3% | -535.8M | -241.4% | -2.88 | +27.1% | -529.6M |
| 2023 | 9.3M | -88.0% | -643.2M | -6,913.9% | -3.95 | -21.2% | -529M |
| 2022 | 77.6M | — | -481.2M | -619.7% | -3.26 | — | -425.8M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 24 Jan 2024 | 37.84 | 37.84 | 36.13 | 36.24 | -2.40% | 1,124,500 | |
| 23 Jan 2024 | 38.51 | 38.74 | 35.87 | 37.13 | -2.39% | 2,003,300 | |
| 22 Jan 2024 | 37.23 | 38.65 | 36.82 | 38.04 | +3.82% | 3,481,100 | |
| 19 Jan 2024 | 37.56 | 37.68 | 36.02 | 36.64 | -2.45% | 1,402,300 | |
| 18 Jan 2024 | 37.57 | 40.65 | 36.32 | 37.56 | +1.76% | 4,264,800 | |
| 17 Jan 2024 | 36.57 | 37.30 | 36.26 | 36.91 | -1.78% | 1,193,800 | |
| 16 Jan 2024 | 37.97 | 38.03 | 36.84 | 37.58 | -2.89% | 1,344,200 | |
| 12 Jan 2024 | 39.94 | 40.42 | 38.06 | 38.70 | -1.33% | 1,426,900 | |
| 11 Jan 2024 | 39.34 | 39.37 | 37.33 | 39.22 | -1.70% | 1,874,200 | |
| 10 Jan 2024 | 39.73 | 40.60 | 39.46 | 39.90 | +0.43% | 1,767,400 | |
| 09 Jan 2024 | 37.82 | 40.33 | 37.82 | 39.73 | +2.56% | 1,607,100 | |
| 08 Jan 2024 | 37.41 | 39.13 | 36.50 | 38.74 | +2.79% | 1,711,700 | |
| 05 Jan 2024 | 36.33 | 37.83 | 35.97 | 37.69 | +2.09% | 1,556,700 | |
| 04 Jan 2024 | 38.02 | 38.49 | 36.56 | 36.92 | -2.46% | 3,141,000 | |
| 03 Jan 2024 | 39.50 | 39.98 | 37.78 | 37.85 | -6.43% | 2,738,100 | |
| 02 Jan 2024 | 39.77 | 40.97 | 39.42 | 40.45 | +0.20% | 1,756,000 | |
| 29 Dec 2023 | 41.75 | 41.80 | 40.31 | 40.37 | -3.44% | 1,355,400 | |
| 28 Dec 2023 | 43.77 | 44.32 | 41.12 | 41.81 | -4.74% | 2,265,000 | |
| 27 Dec 2023 | 42.31 | 43.96 | 41.31 | 43.89 | +4.52% | 1,825,600 | |
| 26 Dec 2023 | 41.82 | 42.25 | 41.29 | 41.99 | +2.26% | 1,470,000 | |
| 22 Dec 2023 | 39.55 | 41.61 | 39.04 | 41.06 | +5.85% | 2,138,800 | |
| 21 Dec 2023 | 38.49 | 39.13 | 37.60 | 38.79 | +1.54% | 3,392,000 | |
| 20 Dec 2023 | 40.02 | 40.76 | 38.12 | 38.20 | -5.02% | 2,550,700 | |
| 19 Dec 2023 | 39.00 | 40.63 | 38.43 | 40.22 | +4.63% | 2,977,400 | |
| 18 Dec 2023 | 39.27 | 40.00 | 37.98 | 38.44 | -2.36% | 2,038,400 |
Page 29 of 51
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026 (opens in a new tab) 03 Nov 2026 12:30
- Should You Invest $1,000 in BridgeBio Pharma Right Now? (opens in a new tab) Motley Fool · 02 Nov 2026 12:05
- Canaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $108 (opens in a new tab) Benzinga · 02 Nov 2026 08:42
- What Is BridgeBio Pharma (BBIO) Betting On With Three FDA Priority Launches? (opens in a new tab) Simply Wall St. · 01 Nov 2026 21:10
- BridgeBio's Heart Disorder Drug Attruby Faces Unanticipated Near-Term Tailwinds, UBS Says (opens in a new tab) MT Newswires · 30 Oct 2026 17:04
- TD Cowen Maintains Buy on BridgeBio Pharma, Lowers Price Target to $100 (opens in a new tab) Benzinga · 30 Oct 2026 14:31
- BridgeBio (BBIO) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 30 Oct 2026 14:29
- Morgan Stanley Maintains Overweight on BridgeBio Pharma, Raises Price Target to $88 (opens in a new tab) Benzinga · 30 Oct 2026 13:46
- BridgeBio Pharma, Inc. Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 30 Oct 2026 12:30
- What BridgeBio Pharma (BBIO) Said on Its Q3 Earnings Call (opens in a new tab) MarketBeat · 30 Oct 2026 00:14
- BridgeBio Pharma (BBIO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (opens in a new tab) Zacks · 29 Oct 2026 20:30
- BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates (opens in a new tab) Zacks · 29 Oct 2026 20:10
- BridgeBio Pharma: Q3 Earnings Snapshot (opens in a new tab) Associated Press · 29 Oct 2026 20:07
- The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics (opens in a new tab) Zacks · 21 Oct 2026 13:06
- What BridgeBio Pharma Doubters Missed (opens in a new tab) Simply Wall St. · 20 Oct 2026 16:12
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 74.27 USD
- Market cap
- 14.5B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 | — |
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 1.7 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 0.0 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 60: free cash flow was negative in two of the last three years
- Thin interest cover: operating profit is only -2.8× the interest
- The last full year was a loss
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 12 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | -214.59× | Weak | 14.98× |
| Price / book | -5.59× | Weak | 3.87× |
| Price / sales | 15.31× | Weak | 3.42× |
| EV / EBITDA | -49.54× | Weak | 13.09× |
| Free cash flow yield | -2% | Weak | 2.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 94.3% | Good | 59.2% |
| Operating margin | -3.3% | Weak | 7.8% |
| Net margin | -59.8% | Weak | 3.4% |
| Return on assets | -14% | Weak | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 86.3% | Good | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | -0.89× | Good | 0.46× |
| Interest cover | -2.82× | Weak | 3.26× |
| Current ratio | 2.09× | Good | 2.35× |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow BBIO and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.